Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer.

PubWeight™: 0.77‹?›

🔗 View Article (PMID 27244887)

Published in Oncotarget on May 09, 2017

Authors

Chia-Sing Lu1, Gia-Shing Shieh2, Chung-Teng Wang1, Bing-Hua Su3, Yu-Chu Su1, Yi-Cheng Chen1, Wu-Chou Su4, Pensee Wu5, Wen-Horng Yang6, Ai-Li Shiau1,7, Chao-Liang Wu1,3

Author Affiliations

1: Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
2: Department of Urology, Tainan Hospital, Ministry of Health and Welfare, Executive Yuan, Tainan, Taiwan.
3: Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
4: Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
5: Institute for Science & Technology in Medicine, Keele University, Keele, United Kingdom.
6: Department of Urology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
7: Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Articles cited by this

Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc (2008) 62.52

Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27

Cancer statistics, 2016. CA Cancer J Clin (2016) 32.95

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer (2008) 18.08

Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov (2005) 9.47

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol (2000) 8.08

Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77

The cancer stem cell: premises, promises and challenges. Nat Med (2011) 6.73

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol (2005) 6.38

Molecular mechanisms of cisplatin resistance. Oncogene (2011) 5.20

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A (2009) 4.19

Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res (1995) 3.04

Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One (2008) 2.90

Cancer stem cells: the challenges ahead. Nat Cell Biol (2013) 2.78

Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control (2003) 2.46

Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev (2012) 2.31

Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res (2008) 2.26

Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One (2010) 2.15

Stem cell pluripotency and transcription factor Oct4. Cell Res (2002) 1.99

Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene (2012) 1.95

Dihydrofolate reductase as a therapeutic target. FASEB J (1990) 1.92

Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res (1981) 1.91

Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer (2010) 1.85

Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin (2013) 1.83

Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology (2010) 1.66

Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells. Cancer Res (2008) 1.55

Mechanisms of recurrence of Ta/T1 bladder cancer. Ann R Coll Surg Engl (2010) 1.48

The effectiveness of retinoic acid treatment in bladder cancer: impact on recurrence, survival and TGFalpha and VEGF as end-point biomarkers. Cancer Biol Ther (2007) 1.47

Retinoic acid represses Oct-3/4 gene expression through several retinoic acid-responsive elements located in the promoter-enhancer region. Mol Cell Biol (1994) 1.37

Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species. J Biol Chem (2011) 1.36

A data integration approach to mapping OCT4 gene regulatory networks operative in embryonic stem cells and embryonal carcinoma cells. PLoS One (2010) 1.31

Oct-4 is critical for survival/antiapoptosis of murine embryonic stem cells subjected to stress: effects associated with Stat3/survivin. Stem Cells (2007) 1.30

Identification of side population cells from bladder cancer cells by DyeCycle Violet staining. Cancer Biol Ther (2008) 1.17

Activation of the transcription factor Oct-1 in response to DNA damage. Cancer Res (2000) 1.07

Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo. Cancer Res (1983) 1.05

Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother Pharmacol (1989) 1.04

Lung cancer tumorigenicity and drug resistance are maintained through ALDH(hi)CD44(hi) tumor initiating cells. Oncotarget (2013) 1.00

Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target. Stem Cells Transl Med (2015) 0.99

Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nat Med (2015) 0.99

All-trans retinoic acid modulates cancer stem cells of glioblastoma multiforme in an MAPK-dependent manner. Anticancer Res (2010) 0.98

Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs. Int J Urol (2008) 0.98

Synergistic effect of combining paeonol and cisplatin on apoptotic induction of human hepatoma cell lines. Acta Pharmacol Sin (2007) 0.98

Therapy-induced enrichment of putative lung cancer stem-like cells. Int J Cancer (2013) 0.96

OCT4 positively regulates Survivin expression to promote cancer cell proliferation and leads to poor prognosis in esophageal squamous cell carcinoma. PLoS One (2012) 0.95

Implications of transcriptional factor, OCT-4, in human bladder malignancy and tumor recurrence. Med Oncol (2011) 0.95

A distinct role for Pin1 in the induction and maintenance of pluripotency. J Biol Chem (2011) 0.95

Identification of CD44 as a surface biomarker for drug resistance by surface proteome signature technology. Mol Cancer Res (2011) 0.94

Mechanisms of drug resistance in chemotherapy for urogenital carcinoma. Int J Urol (1999) 0.93

Intra-articular lentivirus-mediated delivery of galectin-3 shRNA and galectin-1 gene ameliorates collagen-induced arthritis. Gene Ther (2010) 0.91

Unlocking the potential of retinoic acid in anticancer therapy. Br J Cancer (2014) 0.90

Retinoic acid represses invasion and stem cell phenotype by induction of the metastasis suppressors RARRES1 and LXN. Oncogenesis (2013) 0.84

Potent antitumor activity of Oct4 and hypoxia dual-regulated oncolytic adenovirus against bladder cancer. Gene Ther (2015) 0.81

Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models. Clin Cancer Res (2008) 0.81

Acquisition of an enhanced aggressive phenotype in human lung cancer cells selected by suboptimal doses of cisplatin following cell deattachment and reattachment. Cancer Lett (2012) 0.80

Prothymosin α overexpression contributes to the development of pulmonary emphysema. Nat Commun (2013) 0.80

The role of reductive enzymes in cancer cell resistance to mitomycin C. Drug Resist Updat (2000) 0.75